Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Thyssenkrupp Nucera cuts FY 2025/26 EBIT outlook to loss of EUR 105 million-EUR 75 million

Thyssenkrupp Nucera cuts FY 2025/26 EBIT outlook to loss of EUR 105 million-EUR 75 million

ReutersReuters2026/08/11 16:59
  • Thyssenkrupp Nucera scrapped plans to build its own SOEC mass-production, triggering about EUR 30 million one-off negative EBIT effects in Q4 2025/26.
  • Green hydrogen segment EBIT outlook cut to EUR -155 million to EUR -135 million; prior guidance EUR -125 million to EUR -90 million.
  • Green hydrogen revenue view trimmed to EUR 100 million to EUR 130 million; prior EUR 120 million to EUR 170 million; 2024/25 revenue EUR 459 million.
  • Group revenue outlook narrowed to EUR 450 million to EUR 500 million; prior EUR 450 million to EUR 550 million; 2024/25 revenue EUR 845 million.
  • Group EBIT forecast reduced to EUR -105 million to EUR -75 million; prior EUR -80 million to EUR -30 million; order intake seen at EUR 550 million to EUR 670 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thyssenkrupp Nucera AG & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2380956_de) on August 11, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Following Novartis, Novo Nordisk (NVO.US) terminates two cardiovascular clinical trials.

Novo Nordisk (NVO.US) has terminated two additional clinical trials of its experimental cardiovascular drug.

智通财经2026/09/07 11:21
Following Novartis, Novo Nordisk (NVO.US) terminates two cardiovascular clinical trials.